Format

Send to

Choose Destination
Oncoimmunology. 2018 Aug 27;7(12):e1503032. doi: 10.1080/2162402X.2018.1503032. eCollection 2018.

Trial Watch: Oncolytic viro-immunotherapy of hematologic and solid tumors.

G Pol J1,2,3,4,5, Lévesque S1,2,3,4,5, Workenhe ST6,7,8, Gujar S9,10,11,12, Le Boeuf F13,14, R Clements D9, Fahrner JE1,15,16, Fend L16, C Bell J13,14, L Mossman K6,7,8, Fucikova J17,18, Spisek R17,18, Zitvogel L1,15, Kroemer G1,2,3,4,5,19,20,21, Galluzzi L4,22,23.

Author information

1
Gustave Roussy Comprehensive Cancer Institute, Villejuif, France.
2
INSERM, Paris, France.
3
Equipe 11 labellisée par la Ligue Nationale contre le Cancer, Centre de Recherche des Cordeliers, Paris, France.
4
Université Paris Descartes/Paris V, Sorbonne Paris Cité, Paris, France.
5
Université Pierre et Marie Curie/Paris VI, Paris, France.
6
McMaster Immunology Research Centre, McMaster University, Hamilton, ON, Canada.
7
Institute for Infectious Disease Research, McMaster University, Hamilton, ON, Canada.
8
Department of Pathology and Molecular Medicine, McMaster University, Hamilton, ON, Canada.
9
Department of Pathology, Dalhousie University, Halifax, NS, Canada.
10
Department of Microbiology and Immunology, Dalhousie University, NS, Canada.
11
Department of Biology, Dalhousie University, NS, Canada.
12
Centre for Innovative and Collaborative Health Sciences Research, Quality and System Performance, IWK Health Centre, Halifax, NS, Canada.
13
Cancer Therapeutics, Ottawa Hospital Research Institute, Ottawa, ON, Canada.
14
Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON, Canada.
15
INSERM, Villejuif, France.
16
Transgene S.A., Illkirch-Graffenstaden, France.
17
Sotio a.c., Prague, Czech Republic.
18
Department of Immunology, 2nd Faculty of Medicine, University Hospital Motol, Charles University, Prague, Czech Republic.
19
Metabolomics and Cell Biology Platforms, Gustave Roussy Cancer Campus, Villejuif, France.
20
Pôle de Biologie, Hôpital Européen Georges Pompidou, Paris, France.
21
Department of Women's and Children's Health, Karolinska University Hospital, Stockholm, Sweden.
22
Department of Radiation Oncology, Weill Cornell Medical College, New York, NY, USA.
23
Sandra and Edward Meyer Cancer Center, New York, NY, USA.

Abstract

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus supporting the establishment of therapeutically relevant tumor-specific immune responses. In 2015, the US Food and Drug Administration (FDA) approved the oncolytic herpes simplex virus T-VEC for use in advanced melanoma patients. Since then, a plethora of trials has been initiated to assess the safety and efficacy of multiple oncolytic viruses in patients affected with various malignancies. Here, we summarize recent preclinical and clinical progress in the field of oncolytic virotherapy.

KEYWORDS:

CAVATAK; DNX-2401; HF10; MV-NIS; Maraba MG1; Pexa-Vec; REOLYSIN; T-VEC

PMID:
30524901
PMCID:
PMC6279343
[Available on 2019-08-27]
DOI:
10.1080/2162402X.2018.1503032

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center